Trial · NCT03118739
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Serum High Sensitivity C-reactive Protein | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks | -8.002 | 95% Confidence Interval -29.9761 to 20.8680 | Percent change |
| Serum High Sensitivity C-reactive Protein | Placebo | 24 weeks | 9.793 | 95% Confidence Interval -17.8132 to 46.6716 | Percent change |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Diastolic BP, mmHg Baseline | 74.7 | Standard Deviation 9.83 | mm/Hg |
| Clinical Assessments | Placebo | Diastolic BP, mmHg Baseline | 77.8 | Standard Deviation 11.91 | mm/Hg |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Diastolic BP, mmHg 12 weeks (Change from baseline) | 1.6 | Standard Deviation 11.02 | mm/Hg |
| Clinical Assessments | Placebo | Diastolic BP, mmHg 12 weeks (Change from baseline) | -0.2 | Standard Deviation 9.51 | mm/Hg |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Diastolic BP, mmHg 24 weeks (Change from baseline) | 2.0 | Standard Deviation 8.53 | mm/Hg |
| Clinical Assessments | Placebo | Diastolic BP, mmHg 24 weeks (Change from baseline) | 1.7 | Standard Deviation 12.05 | mm/Hg |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Systolic BP, mmHg Baseline | 136.4 | Standard Deviation 15.13 | mm/Hg |
| Clinical Assessments | Placebo | Systolic BP, mmHg Baseline | 138.5 | Standard Deviation 16.34 | mm/Hg |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Systolic BP, mmHg 12 weeks (Change from baseline) | -0.8 | Standard Deviation 19.00 | mm/Hg |
| Clinical Assessments | Placebo | Systolic BP, mmHg 12 weeks (Change from baseline) | -3.2 | Standard Deviation 15.48 | mm/Hg |
| Clinical Assessments | Verinurad 9 mg+Febuxostat 80 mg | Systolic BP, mmHg 24 weeks (Change from baseline) | 0.4 | Standard Deviation 9.75 | mm/Hg |
| Clinical Assessments | Placebo | Systolic BP, mmHg 24 weeks (Change from baseline) | -0.6 | Standard Deviation 17.78 | mm/Hg |
| MRI Variables - LV Mass/End-diastolic Volume | Verinurad 9 mg+Febuxostat 80 mg | 0.049 | Standard Deviation 0.1445 | g/mL | |
| MRI Variables - LV Mass/End-diastolic Volume | Placebo | 0.053 | Standard Deviation 0.1202 | g/mL | |
| Flow Mediated Dilatation (Reactive Hyperemia) | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks Change from Baseline | 0.8 | 95% Confidence Interval -10.59 to 12.24 | Units on a scale |
| Flow Mediated Dilatation (Reactive Hyperemia) | Placebo | 12 weeks Change from Baseline | -5.9 | 95% Confidence Interval -17.04 to 5.29 | Units on a scale |
| Flow Mediated Dilatation (Reactive Hyperemia) | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks Change from Baseline | 0.5 | 95% Confidence Interval -9.44 to 10.47 | Units on a scale |
| Flow Mediated Dilatation (Reactive Hyperemia) | Placebo | 24 weeks Change from Baseline | -5.5 | 95% Confidence Interval -15.47 to 4.44 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/results?page=2